Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Expert Rev Pharmacoecon Outcomes Res ; 21(3): 503-509, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32403958

RESUMO

Background: This study estimated the economic and organisational impact of using subcutaneous injection (SC) formulations of two monoclonal antibodies (rituximab and trastuzumab) in patients with non-Hodgkin's lymphoma (NHL) and HER2 + breast cancer (BC).Methods: The database of the Unit of Oncology and Haematology of the IRST of Meldola was used. The analysis was structured as follows: i) measurement of the volume of Day-Hospital activity; ii) identification of activities and time to complete the administration; iii) estimate the mean cost of an SC or IV (intravenous infusion); iv) estimate the impact of SC formulations on the volumes of activities provided; v) estimate the social impact of SC or IV formulations.Results: The use of an SC formulation was associated a significant reduction in the time that the patient takes to complete the administration (trastuzumab -1 hr 18 min; rituximab -2 hr 24 min) and in consumption of healthcare resources and related costs for trastuzumab (IV: € 1781; SC: € 1701) and rituximab (IV: € 2116; SC: € 1941).Conclusion: The adoption of the SC formulation for rituximab and trastuzumab can generate a greater value for both the national healthcare system and the patient compared to an IV formulation.


Assuntos
Neoplasias da Mama/tratamento farmacológico , Linfoma não Hodgkin/tratamento farmacológico , Rituximab/administração & dosagem , Trastuzumab/administração & dosagem , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/economia , Neoplasias da Mama/economia , Atenção à Saúde/economia , Custos de Medicamentos , Feminino , Humanos , Infusões Intravenosas , Injeções Subcutâneas , Itália , Linfoma não Hodgkin/economia , Projetos Piloto , Receptor ErbB-2/metabolismo , Estudos Retrospectivos , Rituximab/economia , Fatores de Tempo , Trastuzumab/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA